Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: Associations with radiation exposure and histologic grade

Cancer

Volumn 112, Issue 10, 2008, Pages 2143-2151

  Miura, Shiro ^a   Nakashima, Masahiro ^a,f   Ito, Masahiro ^b   Kondo, Hisayoshi ^a   Meirmanov, Serik ^a   Hayashi, Tomayoshi ^c   Soda, Midori ^d   Matsuo, Takeshi ^e   Sekine, Ichiro ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^e Nagasaki Tumor Tissue Registries   (Japan)

^f NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atomic bomb survivors; Breast cancer; Gene amplification; Genomic instability; Radiation

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; ATOMIC BOMB; ATOMIC BOMB SURVIVOR; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C MYC; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WARFARE; NUCLEAR WEAPONS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RADIOACTIVE FALLOUT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SURVIVAL RATE; SURVIVORS;

EID: 43049096400     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23414     Document Type: Article

References (40)

1. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res. 2003;160:381-407.
2. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of 7 studies. Radiat Res. 1995;141:259-277.
3. Carmichael A, Sarni AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol. 2003;29:175-179.
4. Nakashima M, Takamura N, Namba H, et al. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol. 2007;38:621-628.
5. Brown DD. Dawid IB. Specific gene amplification in oocytes. Oocyte nuclei contain extrachromosomal replicas of the genes for ribosomal RNA. Science. 1968;160:272-280.
6. Zimonjic DB, Zhang H, Shan Z, et al. DNA amplification associated with double minutes originating from chromosome 19 in mouse hepatocellular carcinoma. Cytogenet Cell Genet. 2001;93:111-116.
7. Slamon DJ, Clark GM, Wong SG, Levin WI, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
9. Sadamori N, Mine M, Hori M. Skin cancer among atomic bomb survivors [letter]. Lancet. 1989;1:1267.
10. Shibata S, Sadamori N, Mine M, Sekine I. Intracranial meningiomas among Nagasaki atomic bomb survivors [letter]. Lancet 1994;344:1770.
11. Sadamori N, Shibata S, Mine M, et al. Incidence of intracranial meningiomas in Nagasaki atomic bomb survivors. Int J Cancer. 1996;67:318-322.
12. Honda S, Shibata Y, Mine M, et al. Mental health conditions among atomic bomb survivors in Nagasaki. Psychiatry Clin Neurosci. 2002;56:575-583.
13. Nakashima M, Kondo H, Miura S, et al. Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure. Cancer Sci. 2008:99:87-92.
14. Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26:873-879.
15. Thompson DF, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors, part II: solid tumors, 1958-1987. Radiat Res. 1991;137:S17-67.
16. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. 2003;160:707-717.
17. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hyhridization. Proc Natl Acad Sci USA. 1992;89:5321-5325.
18. Press MF, Slamon DJ, Flom KI, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
19. Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
20. Ogura H, Akiyama E, Kasumi F, Kazui T, Sakamoto G. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer. 2003;10:234-240.
21. Berns EM, Foekens JA, van Putten WL, et al. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol. 1992;43:13-19.
22. Roux-Dosseto M, Romain S, Dussault N, et al. C-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer. 1992;28:1600-1604.
23. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 2000:83:1688-1695.
24. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 2003;5:R30-R36.
25. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2000;7:143-164.
26. Castiglioni F, Terenziani M, Carcangiu ML, et al. Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res. 2007;13:46-51.
27. van Gent DC, Hoeijmakers JH, Kamaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet. 2001;2:196-206.
28. Liang F, Han M, Romanienko PJ, Jasin M. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci USA. 1998;95:5172-5177.
29. Moynahan ME, Jasin M. Loss of heterozygosity induced by a chromosomal double-strand break. Proc Natl Acad Sci USA. 1997;94:8988-8993.
30. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;105:697-700.
31. Pipiras E, Coquelle A, Bieth A, Debatisse M. Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome. EMBO J. 1998;17:325-333.
32. Persons DL, Borelli KA, Hsu PH. Quantitation of HER2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997:10:720-727.
33. . Janocko LE, Brown KA, Smith CA, et al. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 2001:46:136-149.
34. Park K, Kwak K, Kim J, Lim S, Han S. c-myc Amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005;36:634-639.
35. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000;7:158-166.
36. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29:231-245.
37. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech. 2002;59:102-108.
38. Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol. 2001;14:1030-1035.
39. Brandt B, Vogt U, Harms F, Bosse U, Zanker KS, Assmann G. Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene. 1995;159:29-34.
40. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in 1000 human breast tumours: correlations with steroid receptors. Eur J Cancer. 1992;28:697-700.